Published in Obesity and Diabetes Week, January 10th, 2005
According to a study from England, "Insulin resistance is a major endocrinopathy underlying the development of hyperglycemia and cardiovascular disease in type 2 diabetes. Metformin (a biguanide) and rosiglitazone (a thiazolidinedione) counter insulin resistance, acting by different cellular mechanisms. The two agents can be used in combination to achieve additive glucose-lowering efficacy in the treatment of type 2 diabetes, without stimulating insulin secretion and without causing hypoglycemia. Both agents also reduce a range of atherothrombotic factors and markers,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week